Introduction
============

Transcranial magnetic stimulation (TMS) is a method for focal non-invasive stimulation of the brain through electromagnetic induction ([@B5]). Application of TMS within the recommended guidelines ([@B98]; [@B99]) is a safe means of triggering or modulating neural activity in a given brain region or network ([@B93]; [@B38]; [@B111]). A form of repetitive TMS (rTMS) known as continuous theta-burst stimulation (cTBS) consists of 50 Hz bursts of three TMS pulses repeated at 5 Hz for a total of 600 pulses over 40 s ([@B58]). The average amplitude of motor evoked potentials (MEPs) induced by single TMS pulses is reduced by approximately 25% for up to 50 min following cTBS of the primary motor cortex (M1) ([@B117]). This neuromodulatory effect is thought to involve mechanisms similar to long-term depression (LTD) ([@B94]; [@B58]; [@B48]). Therefore, the pattern of cTBS-induced changes in MEPs provides a neurophysiologic index of the mechanism of cortical plasticity ([@B92], [@B93]; [@B87], [@B88], [@B90], [@B89]; [@B107]).

The neuromodulatory effect of cTBS applied to M1 or other brain regions has been investigated for its potential as a neurophysiological biomarker and a therapeutic intervention in several neurological and psychiatric disorders ([@B67], [@B66]; [@B33]; [@B76]; [@B14]; [@B88], [@B90]; [@B31], [@B29]; [@B81]; [@B11]; [@B21]; [@B36]; [@B71]; [@B108]; [@B12]). Despite its growing popularity, however, cTBS responses show large inter-individual ([@B49]; [@B44]; [@B74]; [@B113]; [@B46]; [@B52]; [@B56]; [@B61]) and intra-individual variability ([@B114]; [@B113]) that can limit the utility of cTBS for assessing brain plasticity in clinical populations.

Only two published studies have assessed the reproducibility of cTBS aftereffects ([@B114]; [@B113]). The first ([@B114]) used a relatively small sample size (*n* = 10) and did not report reliability coefficients of cTBS aftereffects, which can be compared with the reliability coefficients of other TMS measures ([@B13]; [@B65]; [@B20]; [@B73]; [@B6]; [@B84]; [@B55]; [@B72]; [@B101]; [@B102]; [@B54]; [@B40]). The second study ([@B113]) used an input--output curve approach that allowed assessment of cTBS aftereffects elicited over a range of stimulation intensities, but at the cost of fewer time-points. Specifically, assessments were only performed at 0, 15, and 30 min post-cTBS. This excluded the earliest time points, i.e., 5 and 10 min post-cTBS, which typically exhibit the maximal cTBS effects ([@B117]) and later time-points, i.e., 40--60 min post-cTBS, which capture the longer-lasting TBS effects and have been found to be useful in differentiating clinical populations such as individuals with Alzheimer's disease ([@B39]), autism spectrum disorder ([@B88]), diabetes ([@B41]), and schizophrenia ([@B76]) from healthy individuals. For comparison, at least three studies have assessed the reliability of intermittent theta-burst stimulation (iTBS) aftereffects ([@B55]; [@B40]; [@B103]).

Full characterization of the test--retest reliability of cTBS aftereffects is essential to properly interpret results and plan for future studies. We thus aimed to address this need by systematically assessing the test--retest reliability of cTBS aftereffects in 5- or 10-min intervals for 60 min post-cTBS in a sizeable sample of healthy adults. We also calculated adjusted effect sizes for cTBS aftereffects by taking into account the reliability (or lack thereof) of each cTBS measure ([@B42]; [@B119]; [@B40]). In addition, we explored the effects of age group on the reproducibility of cTBS aftereffects, as well as of single-nucleotide polymorphisms (SNPs) in brain-derived neurotrophic factor (*BDNF*) and apolipoprotein E (*APOE*) genes, which have been found to influence neuroplasticity ([@B115]; [@B18]; [@B85]; [@B2]; [@B96]; [@B69]; [@B16]; [@B30]; [@B61]). Our results can improve the utility of cTBS as a neurophysiologic index of cortical plasticity in neurological and psychiatric disorders, help elucidate the sources of intra-individual variability in cTBS responses, and ensure adequate sample size and power in future cTBS studies in clinical populations.

Materials and Methods {#s1}
=====================

Participants
------------

Twenty-eight healthy adults (25 males, age range: 21--65) participated in the study, which was approved by the local Institutional Review Board in accordance with the Declaration of Helsinki. All participants provided written informed consent prior to enrollment and received monetary compensation upon completion. None of the participants had any TMS contraindication ([@B98]), and all had normal physical and neurological examinations. Individual and group-level demographics are presented in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively.

###### 

Participants' demographics, neuropsychological measures, single-nucleotide polymorphisms, and inter-visit measures.

  ID   Age range (years)   Race          Ethnicity      Education (year)   Handedness   *BDNF*    *APOE*   MMSE   IQ    Verbal KN   Non-verbal FR   Inter-visit interval (days)   Visit-A start time   Visit-B start time   \|Δ~B-A~\| start time (min)
  ---- ------------------- ------------- -------------- ------------------ ------------ --------- -------- ------ ----- ----------- --------------- ----------------------------- -------------------- -------------------- -----------------------------
  1    20--25              White         Non-Hispanic   16                 R            Val/Met   ε3/ε3    30     130   17          13              10                            10:20                11:18                58
  2    26--30              Other         Non-Hispanic   19                 R            Val/Val   ε3/ε4    30     121   17          10              8                             13:50                13:50                0
  3    20--25              Multiracial   Hispanic       16                 R            Val/Val   ε2/ε4    30     106   11          11              33                            14:50                14:52                2
  4    20--25              Multiracial   Non-Hispanic   16                 R            --        --       30     112   11          13              7                             9:55                 9:50                 5
  5    56--60              White         Non-Hispanic   16                 R            Val/Met   ε3/ε3    30     109   13          10              7                             9:36                 9:25                 11
  6    56--60              Black         Non-Hispanic   14                 R            --        --       30     97    9           10              28                            10:50                11:43                53
  7    46--50              White         Non-Hispanic   20+                R            Val/Val   ε3/ε3    30     133   17          14              9                             14:38                13:57                41
  8    20--25              Asian         Non-Hispanic   16                 R            --        --       30     94    8           10              7                             9:27                 9:39                 12
  9    50--55              White         Non-Hispanic   16                 R            Val/Val   ε3/ε4    30     106   13          9               9                             14:00                14:01                1
  10   50--55              White         Non-Hispanic   16                 R            Val/Val   ε3/ε3    30     115   14          11              19                            12:56                14:39                103
  11   60--65              White         Non-Hispanic   16                 R            Val/Met   ε3/ε4    30     118   12          14              7                             11:25                11:22                3
  12   20--25              White         Hispanic       15                 R            Val/Val   ε3/ε4    30     109   14          9               10                            9:42                 9:52                 10
  13   20--25              White         Hispanic       17                 R            Val/Val   ε2/ε3    30     112   10          14              7                             9:47                 9:39                 8
  14   30--35              White         Non-Hispanic   19                 R            Val/Val   ε3/ε3    29     100   9           11              8                             14:33                10:19                254
  15   20--25              White         Non-Hispanic   17                 R            --        --       30     118   13          13              8                             9:46                 9:28                 18
  16   45--50              White         Non-Hispanic   16                 R            --        --       30     94    9           9               28                            14:04                13:36                28
  17   26--30              White         Hispanic       --                 R            Val/Val   ε3/ε3    30     115   13          12              12                            12:04                13:10                66
  18   26--30              White         Hispanic       --                 R            Val/Val   ε3/ε3    29     100   10          10              7                             10:52                10:50                2
  19   50--55              Black         Non-Hispanic   --                 R            --        --       30     97    10          9               11                            9:12                 12:07                175
  20   20--25              White         Non-Hispanic   17                 R            Val/Val   ε2/ε3    30     127   16          13              7                             14:14                14:15                1
  21   20--25              Multiracial   Hispanic       17                 R            Val/Met   ε2/ε3    28     115   12          13              7                             9:50                 10:14                24
  22   45--50              Black         Non-Hispanic   18                 R            Val/Val   ε3/ε4    29     118   16          10              14                            11:29                14:09                160
  23   20--25              Asian         Non-Hispanic   17                 R            Val/Met   ε3/ε4    30     103   9           12              17                            9:41                 9:40                 1
  24   45--50              Black         Non-Hispanic   18                 R            Val/Met   ε3/ε3    30     88    9           7               19                            10:43                10:45                2
  25   30--35              Asian         Non-Hispanic   20+                R            Val/Met   ε3/ε4    30     103   8           13              14                            9:53                 9:41                 12
  26   60--65              Asian         Non-Hispanic   20+                R            Val/Val   ε3/ε4    30     124   15          13              7                             11:02                10:04                58
  27   45--50              White         Non-Hispanic   13                 R            Val/Val   ε3/ε4    30     88    9           7               19                            11:47                13:02                75
  28   30--35              White         Non-Hispanic   20+                L            Val/Met   ε3/ε4    29     97    10          9               20                            13:55                13:48                7
                                                                                                                                                                                                                            

\|Δ

B-A

\|, absolute inter-visit difference; APOE, apolipoprotein E; BDNF, brain derived neurotrophic factor; FR, fluid reasoning; IQ, intelligence quotient; KN, knowledge; Met, methionine; MMSE, Mini-Mental State Examination; Val, valine. Racial and ethnic categories were defined according to the National Institutes of Health policy and guidelines on the inclusion of minorities as subjects in clinical research (

NIH Office of Extramural Research, 2001

).

###### 

Participants' demographics, single-nucleotide polymorphisms, neuropsychological results, and neurophysiological measures for the total sample and for the age and genetic subgroups.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                           All\           Age \< 35\     Age ≥ 45\      *p*        *BDNF* Met-\    *BDNF* Met+\   *p*    *APOE* ε4-\     *APOE* ε4+\     *p*
                                           (*N* = 28)     (*n* = 16)     (*n* = 12)                (*n* = 14)^†^   (*n* = 8)^†^          (*n* = 12)^†^   (*n* = 10)^†^   
  ---------------------------------------- -------------- -------------- -------------- ---------- --------------- -------------- ------ --------------- --------------- -------
  Age (year, mean ± SD)                    36.8 ± 14.5    25.3 ± 4.3     52.1 ± 6.5     N/ A       36.6 ± 14.4     37.8 ± 15.4    0.86   33.8 ± 12.6     40.8 ± 16.1     0.27

  Sex (M : F)                              25 : 3         15 : 1         10 : 2         0.56       13 : 1          8 : 0          1.00   11 : 1          10 : 0          1

  Race (White : non-White)                 16 : 12        9 : 7          7 : 5          1.00       10 : 4          4 : 4          0.39   9 : 3           5 : 5           0.38

  Ethnicity (Hispanic : non-Hispanic)      6 : 22         6 : 10         0 : 12         **0.02**   9 : 5           7 : 1          0.35   7 : 5           9 : 1           0.16

  Education (year, mean ± SD)^∗^           17.0 ± 2.3     17.4 ± 1.9     16.4 ± 2.8     --         17.3 ± 2.4      17.8 ± 2.1     0.69   17.3 ± 1.6      17.7 ± 2.8      --

  *BDNF* (Met- : Met+)^†^                  14 : 8         8 : 5          6 : 3          --         14 : 0          0 : 8          N/A    8 : 4           6 : 4           1.00

  *APOE* (ε4- : ε4+)^†^                    12 : 10        8 : 5          4 : 5          --         8 : 6           4 : 4          1.00   12 : 0          0 : 10          N/ A

  Handedness (Right: Left )                27 : 1         15 : 1         12 : 0         1.00       14 : 0          7 : 1          0.36   12 : 0          9 : 1           0.46

  MMSE score (mean ± SD)                   29.8 ± 0.5     29.7 ± 0.6     29.9 ± 0.3     0.24       29.8 ± 0.4      29.6 ± 0.7     0.52   29.7 ± 0.7      29.8 ± 0.4      0.58

  IQ (mean ± SD)                           108.9 ± 12.3   110.1 ± 10.6   107.2 ± 14.7   0.55       112.4 ± 12.0    107.9 ± 13.1   0.42   112.5 ± 13.2    108.7 ± 11.5    0.49

  Verbal KN score                          11.9 ± 2.9     11.8 ± 3.0     12.2 ± 2.9     0.71       13.1 ± 2.9      11.3 ± 2.9     0.16   12.6 ± 2.9      12.3 ± 3.2      0.83

  Non-verbal FR score                      11.0 ± 2.0     11.6 ± 1.6     10.3 ± 2.4     0.08       11.0 ± 2.0      11.4 ± 2.4     0.70   11.6 ± 2.0      10.6 ± 2.3      0.30

  RMT (% MSO, mean ± SD)                                                                                                                                                 

  Visit A                                  35.3 ± 7.6     35.4 ± 8.7     35.3 ± 6.4     0.97       32.4 ± 5.5      38.1 ± 9.7     0.09   31.2 ± 6.0      37.9 ± 8.2      0.054

  Visit B                                  35.9 ± 7.7     35.9 ± 8.2     35.9 ± 7.4     0.99       33.6 ± 5.8      37.4 ± 10.1    0.27   32.4 ± 6.4      38.0 ± 8.3      0.09

  AMT (% MSO, mean ± SD)                                                                                                                                                 

  Visit A                                  25.9 ± 5.2     26.6 ± 5.9     25.0 ± 4.0     0.44       24.3 ± 3.7      27.3 ± 6.2     0.18   24.6 ± 4.8      26.3 ± 5.1      0.42

  Visit B                                  25.7 ± 4.6     25.9 ± 5.0     25.4 ± 4.3     0.78       24.3 ± 3.2      26.8 ± 5.9     0.21   24.3 ± 4.2      26.3 ± 4.6      0.29

  Baseline MEP amplitude (mV, mean ± SD)                                                                                                                                 

  Visit A                                  1.3 ± 1.5      1.1 ± 1.1      1.5 ± 1.9      0.42       1.2 ± 1.2       0.8 ± 0.5      0.45   1.1 ± 1.3       1.0 ± 0.5       0.75

  Visit B                                  1.1 ± 1.0      1.2 ± 1.0      1.1 ± 1.0      0.82       1.4 ± 1.0       0.7 ± 0.4      0.08   1.2 ± 1.1       0.9 ± 0.5       0.43

  Intervisit interval (days) (mean ± SD)   12.8 ± 7.4     11.4 ± 7.0     14.8 ± 7.8     0.24       12.1 ± 7.3      12.6 ± 5.6     0.86   12.1 ± 7.9      12.5 ± 5.0      0.89

  \|Δ~B-A~\| Start Time (min, mean ± SD)   42.5 ± 62.2    30.0 ± 62.9    59.2 ± 59.7    0.23       55.8 ± 74.6     14.8 ± 19.0    0.15   47.7 ± 72.6     32.7 ± 51.9     0.59

                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comparisons of proportions were conducted with Fisher's exact test. Education and single-nucleotide polymorphisms were not statistically compared between the subgroups because the data were not available for the total sample. The

p

-values were not adjusted for multiple comparisons. The

p

-value \< 0.05 is highlighted in bold font. \|Δ

B-A

\|, absolute inter-visit difference; AMT, active motor threshold;

APOE

, apolipoprotein E;

APOE

ε4+, ε2/ε4 or ε3/ε4 genotype;

APOE

ε4--, ε2/ε3 or ε3/ε3;

BDNF

, brain-derived neurotrophic factor;

BDNF

Met--, Val66Val;

BDNF

Met+, Val66 Met; FR, fluid reasoning; IQ, intelligence quotient; KN, knowledge; MEP, motor evoked potential; Met, metionine; MMSE, Mini-Mental State Examination; MSO, maximum stimulator output; RMT, resting motor threshold; SD, standard deviation; Val, valine.

∗

Education data were available for 26 participants.

†

BDNF

and

APOE

results were available for 22 participants.

Neuropsychological Testing
--------------------------

Mini-Mental State Examination ([@B35]; [@B27]) and the Abbreviated Battery of Stanford--Binet IV intelligence scale ([@B109]), including Verbal Knowledge and Non-Verbal Fluid Reasoning subscores, were completed.

Genetic Analyses
----------------

Saliva samples from 22 participants were assessed for *BDNF* Val66Met polymorphism and the presence of *APOE* ε4 allele, as reported previously ([@B61]). Aliquot (700 μL) extraction of genomic DNA was performed on saliva samples collected using the Oragene Discover OGR-250 Kit (DNA Genotek Inc., Ottawa, ON, Canada). DNA was extracted from samples using standard methodology and the prepIT L2P reagent ([@B32]). The rs6265 SNP of the *BDNF* gene, and the rs429358 and the rs7412 SNPs of the *APOE* gene were analyzed using a TaqMan single-tube genotyping assay, which uses polymerase chain reaction (PCR) amplification and a pair of fluorescent dye detectors that target the SNP. During PCR, the polymerase released the fluorescent probe into solution where it was detected using endpoint analysis in an 7900HT Real-Time instrument from Applied Biosystems, Inc. (Foster City, CA, United States).

Transcranial Magnetic Stimulation
---------------------------------

Two identical TMS visits (7--33 days apart; median interval = 9.5 days) were conducted. The starting times of the two visits were 0--254 min apart (interquartile range = 1--103 min; median = 12 min). The inter-visit intervals and starting-time differences for individual subjects are presented in [Table 1](#T1){ref-type="table"}.

All TMS procedures followed the recommended guidelines endorsed by the International Federation of Clinical Neurophysiology ([@B98]; [@B99]). Participants were seated in a comfortable chair with the right arm and hand in a natural pronated ∼90° angle on a pillow in front of them. They were instructed to keep their right hand as still and relaxed as possible throughout the experiment. They were also monitored for drowsiness and were asked to keep their eyes open during the TMS application. Single TMS pulses and cTBS were applied to the left primary motor cortex (M1) at 120% of individual resting motor threshold (RMT) and 80% of active motor threshold (AMT), respectively, as biphasic pulses with an antero-posterior--postero-anterior (AP-PA) induced current direction using a MagPro X100 stimulator and a MC-B70 Butterfly Coil (outer diameter: 97 mm; MagPro, MagVenture A/S, Farum, Denmark). The coil was held tangentially to the participant's head surface, with the handle pointing occipitally and positioned at 45° relative to the mid-sagittal axis of the participant's head. The optimal spot for the maximal responses of the right first dorsal interosseous (FDI) muscle ("motor hotspot") was localized. A Polaris infrared-optical tracking system (Northern Digital Inc., Waterloo, ON, Canada) and a Brainsight TMS neuronavigation system (Rogue Research Inc., Montreal, QC, Canada) with a brain MRI template (for 21 participants) or the participant's brain MRI (for the remaining 7 participants) was used to ensure consistent targeting throughout the experiment.

Surface electromyogram (EMG) was recorded from the right FDI with a PowerLab 4/25 data-acquisition device and LabChart 8 software (AD Instruments, Colorado Springs, CO, United States). Electrodes were placed over the FDI belly (negative) and the first interphalangeal joint of the second finger (positive). The ground electrode was placed over the ipsilateral ulnar styloid process. The TMS system delivered triggered pulses that synchronized the TMS and EMG systems. EMG signal was digitized at 1 kHz for 500 ms following each stimulus trigger and 100 ms pre-trigger, amplified with a range of ±10 mV (band-pass filter 0.3--1000 Hz).

Each TMS session began by localizing the motor hotspot for FDI and assessment of the RMT, defined as the lowest intensity of stimulation that elicited MEPs ≥ 50 μV in at least five of ten pulses in the relaxed right FDI. To assess pre-cTBS cortico-motor reactivity, three blocks of 30 single TMS pulses were applied to M1, with a 5--10 min inter-block interval and at a random 4--6 s inter-pulse interval. In each block, individual MEPs \> 2.5 SD from the mean were excluded. Baseline MEP amplitude was calculated as the average of the peak-to-peak amplitude of MEPs in the three blocks. The AMT was then assessed as the lowest intensity that elicited MEPs ≥ 200 μV in at least five of ten pulses with the FDI slightly contracted. After a 5-min break, during which participants were instructed to maintain hand relaxation to control the effects of voluntary hand movements on cTBS responses ([@B60]), cTBS was applied as 200 bursts of three pulses at 50 Hz, repeated at 200-ms intervals for 40 s (for a total of 600 pulses). Cortico-motor reactivity was reassessed at 5, 10, 15, 20, 30, 40, 50, and 60 min post-cTBS (*T5*--*T60*).

Statistical Analyses
--------------------

Stata software version 13.1 (StataCorp, College Station, TX, United States) and MATLAB and Statistics and Machine Learning Toolbox R2016b (The MathWorks, Natick, MA, United States) were used for data analysis. Data from each TMS visit included: (a) RMT and AMT, expressed as percentage of maximum stimulator output; (b) baseline MEP amplitude, calculated as the average of baseline MEP amplitude in 3 blocks of 30 single TMS pulses; and (c) percent change in the average amplitude of 30 MEPs at T5--T60 relative to baseline (%Δ) for each participant.

The Shapiro--Wilk test found significant deviations in MEP values from normal distribution; thus, natural log-transformed, baseline-corrected MEP amplitude at each post-cTBS time point (ΔMEP) was averaged over all participants separately for each visit. The following measures were also calculated: absolute MEP modulation at T5--T60 (\|ΔMEP\|), maximum suppression and maximum modulation of MEPs during 60 min post-cTBS, area under-the-curve (AUC) and the absolute AUC value (\|AUC\|) of ΔMEPs over T0--T10, ..., and T0--T60 intervals. Cumulative AUC and \|AUC\| measures up to each time-point were calculated as the summed products of the average ΔMEP and the average \|ΔMEP\|, respectively, across each two consecutive time-points and the time in minutes between them.

Grand-average values for all cTBS measures were calculated separately for both visits and were compared against zero using one-sample *t-*tests. Visit-B *minus* visit-A difference (Δ~B-A~) and \|Δ~B-A~\| were calculated for each neurophysiological measure ([Table 3](#T3){ref-type="table"}). All analyses were two-tailed, and the α level was set to 0.05. When explicitly noted, false discovery rate (FDR) was used to adjust *p*-values for multiple testing ([@B7]; [@B8]).

###### 

Neurophysiological measures (mean ± SD) and their test-retest reliability for the whole sample (*N* = 28).

                                  Reproducibility-adjusted effect sizes                                                                                                     
  ------------------------------- --------------------------------------- ------------- -------------- -------------- -------------- -------------- --------- ------ ------ ------
  Motor threshold (% MSO)                                                                                                                                                   
                                  RMT                                     35.3 ± 7.6    35.9 ± 7.7     0.6 ± 2.2      1.8 ± 1.4      **0**.**96**   \<0.001   0.20   0.50   0.79
                                  AMT                                     25.9 ± 5.2    25.7 ± 4.6     -0.2 ± 1.8     1.5 ± 1.1      **0**.**93**   \<0.001   0.20   0.49   0.78
  Baseline MEP amplitude (mV)     1.3 ± 1.5                               1.1 ± 1.0     -0.2 ± 1.0     0.6 ± 0.8      **0**.**70**   \<0.001        0.18      0.46   0.72   
  Post-cTBS ΔMEP                                                                                                                                                            
                                  T5                                      -0.05 ± 0.3   -0.07 ± 0.4    -0.02 ± 0.5    0.41 ± 0.3     0.16           0.213     0.13   0.31   0.48
                                  T10                                     -0.02 ± 0.4   0.08 ± 0.4     0.11 ± 0.5     0.42 ± 0.3     0.11           0.289     0.12   0.28   0.44
                                  T15                                     0.09 ± 0.3    0.00 ± 0.3     -0.09 ± 0.5    0.40 ± 0.3     -0.16          0.791     \-     \-     \-
                                  T20                                     0.10 ± 0.3    0.03 ± 0.4     -0.07 ± 0.5    0.39 ± 0.3     0.20           0.157     0.13   0.33   0.51
                                  T30                                     0.07 ± 0.4    -0.02 ± 0.5    -0.09 ± 0.5    0.36 ± 0.4     **0**.**37**   0.024     0.16   0.39   0.61
                                  T40                                     0.07 ± 0.4    -0.06 ± 0.5    -0.14 ± 0.5    0.40 ± 0.3     0.26           0.076     0.14   0.35   0.55
                                  T50                                     0.08 ± 0.4    0.07 ± 0.5     -0.01 ± 0.5    0.37 ± 0.3     **0**.**53**   0.002     0.17   0.42   0.67
                                  T60                                     -0.04 ± 0.5   0.03 ± 0.6     0.08 ± 0.8     0.61 ± 0.5     -0.08          0.653     \-     \-     \-
  Maximum suppression             -0.50 ± 0.5                             -0.53 ± 0.5   -0.03 ± 0.6    0.45 ± 0.3     **0**.**38**   0.024          0.16      0.39   0.61   
  Post-cTBS \|ΔMEP\|                                                                                                                                                        
                                  T5                                      0.29 ± 0.2    0.33 ± 0.2     0.04 ± 0.3     0.29 ± 0.2     -0.27          0.912     \-     \-     \-
                                  T10                                     0.31 ± 0.2    0.28 ± 0.2     -0.03 ± 0.4    0.27 ± 0.2     -0.18          0.815     \-     \-     \-
                                  T15                                     0.26 ± 0.2    0.26 ± 0.2     0.00 ± 0.3     0.21 ± 0.1     0.11           0.297     0.11   0.28   0.44
                                  T20                                     0.29 ± 0.2    0.33 ± 0.3     0.03 ± 0.3     0.22 ± 0.1     0.29           0.068     0.15   0.36   0.57
                                  T30                                     0.33 ± 0.3    0.37 ± 0.3     0.03 ± 0.3     0.20 ± 0.2     **0**.**50**   0.003     0.17   0.42   0.66
                                  T40                                     0.32 ± 0.2    0.32 ± 0.3     0.00 ± 0.4     0.24 ± 0.3     0.17           0.190     0.13   0.32   0.49
                                  T50                                     0.33 ± 0.3    0.35 ± 0.3     0.02 ± 0.4     0.29 ± 0.2     **0**.**34**   0.037     0.15   0.38   0.59
                                  T60                                     0.37 ± 0.3    0.44 ± 0.4     0.07 ± 0.5     0.35 ± 0.3     -0.03          0.567     \-     \-     \-
  Maximum modulation (\|ΔMEP\|)   0.76 ± 0.4                              0.86 ± 0.4    0.10 ± 0.4     0.35 ± 0.3     **0**.**31**   0.045          0.15      0.37   0.58   
  AUC of ΔMEPs                                                                                                                                                              
                                  T0--T10                                 -0.33 ± 2.3   -0.15 ± 2.4    0.18 ± 3.1     2.55 ± 1.6     0.13           0.257     0.12   0.29   0.46
                                  T0--T15                                 -0.16 ± 3.6   0.05 ± 3.4     0.21 ± 4.6     3.94 ± 2.2     0.15           0.228     0.12   0.31   0.48
                                  T0--T20                                 0.31 ± 4.7    0.10 ± 4.6     -0.20 ± 6.0    5.14 ± 2.9     0.18           0.183     0.13   0.32   0.50
                                  T0--T30                                 1.13 ± 7.2    0.15 ± 8.0     -0.99 ± 9.2    7.41 ± 5.4     0.27           0.078     0.14   0.36   0.56
                                  T0--T40                                 1.85 ± 10.2   -0.26 ± 11.9   -2.12 ± 13.2   10.28 ± 8.3    0.29           0.061     0.15   0.36   0.57
                                  T0--T50                                 2.60 ± 13.3   -0.25 ± 15.4   -2.85 ± 16.2   12.70 ± 10.2   **0**.**36**   0.026     0.16   0.38   0.60
                                  T0--T60                                 2.77 ± 16.5   0.26 ± 19.1    -2.51 ± 19.7   15.94 ± 11.5   **0**.**40**   0.018     0.16   0.39   0.62
  \|AUC\| of ΔMEP                                                                                                                                                           
                                  T0--T10                                 2.22 ± 1.2    2.36 ± 1.4     0.14 ± 2.1     1.74 ± 1.2     -0.35          0.961     \-     \-     \-
                                  T0--T15                                 3.63 ± 1.7    3.70 ± 2.1     0.07 ± 3.1     2.51 ± 1.8     -0.32          0.946     \-     \-     \-
                                  T0--T20                                 5.02 ± 2.1    5.16 ± 2.7     0.14 ± 3.5     2.72 ± 2.2     -0.08          0.647     \-     \-     \-
                                  T0--T30                                 8.15 ± 3.3    8.64 ± 4.1     0.48 ± 4.4     3.48 ± 2.7     0.31           0.053     0.15   0.37   0.58
                                  T0--T40                                 11.42 ± 5.0   12.05 ± 6.2    0.64 ± 6.2     4.66 ± 4.0     **0**.**39**   0.018     0.16   0.39   0.61
                                  T0--T50                                 14.66 ± 6.7   15.37 ± 8.3    0.71 ± 7.9     5.96 ± 5.2     **0**.**45**   0.008     0.16   0.41   0.64
                                  T0--T60                                 18.17 ± 8.1   19.33 ± 10.6   1.16 ± 9.9     6.00 ± 0.1     **0**.**46**   0.007     0.16   0.41   0.64
                                                                                                                                                                            

AUC and \|AUC\| of ΔMEPs were calculated as the summed products of the average ΔMEP and the average \|ΔMEP\|, respectively, across two consecutive time-points and the time in minutes between them. The ICC values with

p

\< 0.05 are highlighted in bold font. Abbreviations: Δ

B-A

, Visit B minus Visit A; \|Δ

B-A

\|, absolute inter-visit difference; AMT, active motor threshold; AUC, area under-the-curve; ΔMEP, natural log-transformed, baseline-corrected MEP amplitude; ICC, intraclass correlation coefficient; MEP, motor evoked potential; MSO, maximum stimulator output; RMT, resting motor threshold; T0--Tn, over the first n minutes following cTBS.

ΔMEPs at T10 and T40 were previously found to be the best predictors of *inter*-individual variability in cTBS aftereffects in visit-A ([@B61]). Thus, to assess the effect of potential covariates on the *intra*-individual variability of cTBS aftereffects at T10 and T40, we conducted linear mixed-effects (LME) regression analyses with Δ*MEPs at T10* or *T40* as dependent variable, *Visit* (visit-A vs. visit-B) as a within-subject factor, and potential covariates including RMT, AMT, baseline MEP amplitude, number of days between the two visits (*Inter-visit Interval*), and the absolute inter-visit difference in starting time (in minutes) (*Time Difference*) as between-subject factors. Based on previous studies that found in many situations a regression model is likely to be reliable when the number of candidate predictors is smaller than one-tenth of the number of subjects ([@B50]) (p. 72), up to three between-subjects predictors were considered for simultaneous inclusion in any regression model.

To assess test--retest reliability, intraclass correlation coefficients (ICCs) ([@B97]) were calculated in the form of absolute agreement between the two visits for all neurophysiological measures. ICCs were calculated using a two-way mixed-effects model, with fixed column (C) effects and random row (R) effects ([@B78]):
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where ICC(A,1) represents the degree of absolute agreement of measurements made under the two fixed levels of the column factor. *k* = the number of raters/measurements per subject; *MS~R~* = mean square for rows (representing the individual subjects); *MS~E~* = mean square error; *MS~C~* = mean square for columns (representing the two visits); *n* = the number of subjects.

Using this formula, ICC = 1 indicates maximum reliability and ICC ≤ 0 indicates no reliability \[in the case that the within-group variance is equal to or higher than the between-groups variance ([@B64])\]. ICC values were interpreted as follows ([@B97]): (i) ICC \< 0.25: very low to no reliability; (ii) 0.25 ≤ ICC \< 0.50: low reliability; (iii) 0.50 ≤ ICC \< 0.75: moderate reliability; and (iv) ICC ≥ 0.75: high reliability. ICC values were statistically compared using two-way mixed-effects *F* statistics ([@B78], Table 8). The effects on the ICCs of covariates that had a significant effect on ΔMEPs were assessed by including the covariate in the corresponding mixed-effects regression model and re-calculating the residual intraclass correlation.

Lack of reliability of a measure of interest attenuates the observed effect size compared to the population parameter ([@B59]). Following previously applied methodology ([@B42]; [@B119]; [@B40]), we assessed how test--retest reliability (or lack thereof) of TMS measures would attenuate small, medium, and large effect sizes, i.e., Cohen's *d* values of 0.2, 0.5, and 0.8 ([@B26]), respectively, which assume perfect reproducibility. First, each *idealized* Cohen's *d* is converted to an *r* ([@B25]) (p. 23):
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This idealized *r* is then *adjusted* for unreliability using the ICC ([@B119]):
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Finally, the adjusted *r* is converted back to an adjusted *d* ([@B42]) (p. 246):
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Exploratory Analyses
--------------------

Though unintended, the age of our participants conformed to a bimodal distribution. Thus, to explore the impact of age on our reliability measures, the total sample was subdivided into two distinct age groups with a 10-year gap and a ∼27-year difference in mean age: a *Younger* group with age \< 35 (*n* = 16; range: 21--34; mean ± SD, 25.3 ± 4.3) and an *Older* group with age ≥ 45 (*n* = 12; range: 45--65; mean ± SD, 52.1 ± 6.5). To explore the effect of age on the test--retest reliability of cTBS aftereffects: (i) the ICC values of TMS measures were calculated separately for the two age groups; (ii) separate repeated-measures analyses of variance (Rm-ANOVAs) were conducted with *ΔMEP at T10* or *T40* as dependent variable, *Age Group* as a between-subjects factor, *Visit* as a within-subject factor, and *Age Group* × *Visit* interaction. Because the proportion of Hispanic participants was significantly higher in the Younger group than in the Older group, we assessed the effect of *Ethnicity* as a categorical covariate in these Rm-ANOVAs. We also re-calculated all the ICCs for the Younger group while controlling for *Ethnicity*.

To explore the roles of *BDNF* and *APOE* SNPs in the reliability of TMS measures, we calculated the ICC values of neurophysiological measures over the two visits separately for participants with *BDNF* Val/Val (Met--; *n* = 14) and Val/Met (Met+; *n* = 8) genotypes as well as for those with *APOE* ε2/ε3 or ε3/ε3 (ε4--; *n* = 12) and *APOE* ε2/ε4 or ε3/ε4 (ε4+; *n* = 10) genotypes.

Because *BDNF* was previously found to influence the cTBS aftereffect at T10 ([@B61]), we assessed the cTBS aftereffects separately for *BDNF* Met-- and Met+ participants in each visit and conducted a Rm-ANOVA with *ΔMEP at T10* as dependent variable, *BDNF Status* (Met-- vs. Met+) as a between-subjects factor, *Visit* (visit-A vs. visit-B) as a within-subject factor, and *BDNF Status* × *Visit* interaction. Further, we assessed the effect of *BDNF Status* as a covariate in the LME regression analyses at T10.

Results
=======

Demographics, neuropsychological measures, inter-visit interval, starting times of the two visits, and inter-visit differences in starting time for individual participants are presented in [Table 1](#T1){ref-type="table"}. Statistical comparisons of these measures between the two age groups are presented in [Table 2](#T2){ref-type="table"}.

Genetic Analyses
----------------

Available *BDNF* and *APOE* results and comparisons of all available measures between *BDNF*/*APOE* subgroups are presented in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively.

Among 22 participants with available DNA results, the frequencies of *BDNF* Val/Val and Val/Met genotypes were 0.64 and 0.36, respectively, while the frequencies of *APOE* ε2/ε3, ε3/ε3, and ε3/ε4 genotypes were 0.14, 0.41, and 0.46, respectively. *BDNF* and *APOE* subgroups were comparable in all available measures ([Table 2](#T2){ref-type="table"}).

Baseline Neurophysiological Measures
------------------------------------

The RMT, AMT, and baseline MEP amplitude in each visit and their inter-visit differences are summarized in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively.

There were no significant differences in any of the baseline neurophysiological measures in either visit between age or genetic subgroups ([Table 2](#T2){ref-type="table"}). There was also no significant difference between the two visits in any of the baseline neurophysiological measures for the whole sample (*p*'s \> 0.14), for each age group (*p*'s \> 0.17), or for each *BDNF* (*p*'s \> 0.08) or *APOE* (*p*'s \> 0.28) subgroup.

The LME regression analyses of ΔMEP at T10 found a significant, negative effect of *Time Difference* in all models (*p*'s \< 0.025), but no significant effect of any of the baseline neurophysiological measures or *Visit* (*p*'s \> 0.21). LME regression analyses of ΔMEP at no other time point found a significant effect of *Time Difference* (*p*'s \> 0.41).

cTBS-Induced Plasticity Results
-------------------------------

Grand-average ΔMEPs in visits A and B are shown in [Figure 1](#F1){ref-type="fig"}. ΔMEP and \|ΔMEP\| values, maximum suppression and maximum modulation as well as their inter-visit differences are summarized in [Table 3](#T3){ref-type="table"}. Grand-average ΔMEPs did not significantly differ from zero at any time point in either visit (*p*'s \> 0.11). There was also no significant difference in grand-average ΔMEP or \|ΔMEP\| between the two visits at any time point (*p*'s \> 0.16).

![Grand-average ΔMEPs recorded from the right FDI muscle at 5 to 60 min following cTBS of the left primary motor cortex in two identical visits. The ΔMEPs did not significantly differ from zero at any post-cTBS time point in either visit (*p*'s \> 0.11). Error bars represent standard error of the mean. cTBS, continuous theta-burst stimulation; ΔMEP, natural log-transformed, baseline-corrected amplitudes of the motor evoked potential; FDI, first dorsal interosseous.](fnins-13-00447-g001){#F1}

The ΔMEPs in the Older group were significantly greater than zero at T20 in visit-A (*P*~FDR~ = 0.029), but not at any other time point in either visit (*p*'s \> 0.18). The ΔMEPs in the Younger group did not significantly differ from zero at any time point in either visit (*p*'s \> 0.06). The ΔMEPs in the *BDNF* Met-- group were significantly less than zero at T10 in visit-A (*P*~FDR~ = 0.042), but not at any other time point in either visit (*p*'s \> 0.14). The ΔMEPs in the *BDNF* Met+ group were not significantly different from zero at any time point in either visit (*P*~FDR~'s \> 0.05). cTBS aftereffects in both visits for the two age subgroups and the two *BDNF* subgroups are presented in [Figure 2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"} respectively.

![Average ΔMEPs recorded from the right FDI muscle at 5 to 60 min following cTBS of the left primary motor cortex in two identical visits in the Younger **(A)** and Older **(B)** groups. The ΔMEPs did not significantly differ from zero at any time point in either visit in the Younger group (*p*'s \> 0.06). ^∗^The ΔMEPs in the Older group were significantly greater than zero at T20 in visit-A (*P*~FDR~ = 0.029), but not at any other time point in either visit (*p*'s \> 0.18). Error bars represent standard error of the mean. cTBS, continuous theta-burst stimulation; ΔMEP, natural log-transformed, baseline-corrected amplitudes of the motor evoked potential; FDI, first dorsal interosseous; FDR, false discovery rate.](fnins-13-00447-g002){#F2}

The Rm-ANOVA on the ΔMEP at T10 found a significant effect of *BDNF* status, *F*(1, 20) = 8.28, *p* = 0.009, $\eta_{p}^{2}$ = 0.29, but no significant effects of Visit or *BDNF* × *Visit* interaction (*p*'s \> 0.10). *BDNF* Met-carrier status had a significant positive effect in all LME regression analyses of ΔMEP at T10 (${\hat{B}}^{\prime}$s \> 0.28, *p*'s \< 0.027). There was no other significant effect in any of the LME models (*p*'s \> 0.08).

To control for potential effects of gender, race/ethnicity, and handedness on cTBS-induced plasticity measures, we calculated ΔMEP's at T5--T60 in a subgroup of White, non-Hispanic, and right-handed males (*n* = 11, [Table 1](#T1){ref-type="table"}). In this smaller, but more-homogenous subsample, ΔMEPs did not significantly differ from zero at any time point in either visit (*p*'s \> 0.23).

Test--Retest Reliability of TMS Measures
----------------------------------------

Measures of inter-visit variability and test--retest reliability for RMT, AMT, baseline MEP amplitude and cTBS measures, as well as reliability-adjusted effect sizes for each TMS measure in the whole group are presented in [Table 3](#T3){ref-type="table"}.

The ICCs of baseline neurophysiological measures was not significantly different between the two age groups (*p*'s \> 0.19; [Figure 3](#F3){ref-type="fig"}). In contrast, ΔMEPs in the Younger group were significantly more reliable than in the Older group at T10 and T60 (*P*~FDR~'s \< 0.015), but not at other individual time points (*P*~FDR~'s *\>* 0.058). Similarly, \|AUC\| measures were significantly more reliable in the Younger group than in the Older group over T0--T20 and beyond (*P*~FDR~'s \< 0.001; [Figure 3](#F3){ref-type="fig"}). The reliability of other cumulative ΔMEP measures was not significantly different between the two age groups (*p*'s \> 0.058). After adjusting for *Ethnicity*, none of the ICCs in the Younger group crossed our pre-defined boundaries for interpretation of ICC values (see "Materials and Methods" section).

![Test--retest reliability of baseline neurophysiological measures and post-cTBS ΔMEP measures separately in the Younger (age \< 35, *n* = 16) and Older (age ≥ 45, *n* = 12) groups. \|AUC\| of ΔMEPs were calculated as the summed products of the average \|ΔMEP\| across each two consecutive time-points and the time in minutes between them over T0--T10, T0--15, ..., T0--T60 intervals (marked by their end time point on the abscissa). The ICCs of the RMT, AMT, and baseline MEP amplitude were not significantly different between the two age groups (*p*'s \> 0.19). The \|AUC\| of ΔMEPs were significantly more reliable in the Younger group than in the Older group over T0--T15 and beyond (*P*~FDR~'s \< 0.001). The reliability of other cumulative ΔMEP measures was not significantly different between the two age groups (*p*'s \> 0.058). AUC, area under-the-curve; cTBS, continuous theta-burst stimulation; FDR, false discovery rate; ΔMEP, natural log-transformed, baseline-corrected MEP amplitude; ICC, intraclass correlation coefficient; MEP, motor evoked potential; T0--T*n*, over the first *n* minutes post-cTBS.](fnins-13-00447-g003){#F3}

To control for potential effects of gender, race/ethnicity, and handedness on the test--retest reliability of cTBS aftereffects, we calculated the ICC values of baseline neurophysiological measures and ΔMEP's at T5--T60 among White, non-Hispanic, and right-handed males (*n* = 11, [Table 1](#T1){ref-type="table"}). The ICC values of RMT, AMT, and baseline MEP amplitude in this subgroup were 0.86 (*p* \< 0.001), 0.96 (*p* \< 0.001), and 0.75 (*p* = 0.003), respectively. The ICC values of ΔMEP at T5, T10, T15, T20, T30, T40, T50, and T60 in this subgroup were 0.54 (*p* = 0.031), --0.09 (*p* = 0.602), 0.18 (*p* = 0.297), 0.71 (*p* = 0.005), 0.86 (*p* \< 0.001), 0.67 (*p* = 0.008), 0.79 (*p* = 0.001), and 0.17 (*p* = 0.309), respectively.

The ICCs of baseline neurophysiological measures were not significantly different between either the *BDNF* or the *APOE* subgroups (*p*'s \> 0.16; [Figure 5](#F5){ref-type="fig"}). In contrast, ΔMEPs were significantly more reliable in *BDNF* Met-- participants than in *BDNF* Met+ participants at T20--T40 (*P*~FDR~'s \< 0.023), but not at other time points (*p*'s \> 0.24). Maximum suppression, maximum modulation, and AUC of ΔMEPs over T0--T30 and beyond were significantly more reliable in *BDNF* Met-- participants than in *BDNF* Met+ participants (*P*~FDR~'s \< 0.032; [Figure 5](#F5){ref-type="fig"}). The reliability of other cumulative ΔMEP measures was not significantly different between the two *BDNF* subgroups (*P*~FDR~ \> 0.21).

ΔMEPs were significantly more reliable in *APOE* ε4-- participants than in *APOE* ε4+ participants at T5 and T20--T40 (*P*~FDR~'s \< 0.024), but not at other time points (*P*~FDR~'s \> 0.07). All AUC measures were significantly more reliable in *APOE* ε4-- participants than in *APOE* ε4+ participants (*P*~FDR~'s \< 0.021; [Figure 5](#F5){ref-type="fig"}). There were no significant differences in the reliability of maximum suppression or maximum modulation between the two *APOE* subgroups (*P*~FDR~'s \> 0.27).

Discussion
==========

Test--retest reliability of TMS measures influences their utility as potential neurophysiologic biomarkers or targets for therapeutic intervention. As the use of plasticity-inducing rTMS protocols becomes more common, it is necessary to investigate the magnitude and sources of their inter- and intra-individual variability. While some of the factors that contribute to the inter-individual variability of these types of plasticity metrics among healthy individuals have been identified ([@B18], [@B17]; [@B2]; [@B49]; [@B44]; [@B74]; [@B82], [@B83]; [@B113]; [@B107]; [@B56]; [@B61]), few studies have assessed the intra-individual reliability of cTBS responses ([@B114]; [@B113]) and no study, to our knowledge, has systematically assessed the test--retest reliability of cTBS aftereffects during 60 min post-cTBS. The present study was designed to fill this gap by assessing the test--retest reliability of cTBS aftereffects at 5- or 10-minute intervals (T5--T60) and of cumulative cTBS aftereffects during 60 min post-cTBS in healthy adults. Furthermore, in order to provide guidance and reference for future studies, we calculated adjusted effect sizes that take into account the test--retest reliability of cTBS measures. Finally, we explored the influences of age group and common SNPs in *BDNF* and *APOE* genes on the reliability of cTBS aftereffects.

Overall Reliability of Baseline Neurophysiological Measures
-----------------------------------------------------------

Resting motor threshold had high test--retest reliability ([Table 3](#T3){ref-type="table"}), which was comparable with the ICC values reported in most previous studies ([@B13]; [@B65]; [@B73]; [@B6]; [@B84]; [@B55]; [@B102]; [@B40]; [@B28]) and somewhat higher than other studies that found RMT ICCs in the 0.75--0.80 range ([@B34]; [@B72]; [@B101]; [@B54]). The AMT also had high test--retest reliability ([Table 3](#T3){ref-type="table"}), which was comparable with the results of previous studies ([@B84]; [@B55]; [@B40]).

Baseline MEP amplitude had moderate test--retest reliability ([Table 3](#T3){ref-type="table"}). The ICC of baseline MEP amplitude found in the present study (ICC = 0.70) was moderate compared to the wide range of ICC values for baseline MEP amplitude (--0.16 to 0.87) reported in previous studies ([@B63]; [@B77]; [@B20]; [@B34]; [@B84]; [@B55]; [@B54]; [@B40]; [@B28]). Variability of baseline MEP amplitude was previously found to be associated with variability of TBS aftereffects ([@B56]; [@B40]). The moderate reliability of baseline MEP amplitude in the present study suggests that such variability was not the main cause of the low reliability of some of the cTBS measures reported here.

Overall Reliability of cTBS Aftereffects
----------------------------------------

The finding that differences between the start times of the two visits influenced the cTBS aftereffects at T10 could be due to the effect of circadian rhythm on the neuromodulatory effects of rTMS arising from changes in cortical excitability and synaptic efficiency during the day ([@B24]). While the present results cannot definitively conclude that circadian factors influenced the intra-individual variability in plasticity at T10, future studies could attempt to control for the time of day or, perhaps even better, to individualize visits to coincide with the same relative point in each subject's circadian cycle.

The finding that T5 had one of the lowest between-visit variabilities among post-cTBS time points is consistent with the findings of a previous study ([@B114]). Importantly, however, the low between-visit variability of cTBS aftereffects at T5 and T50 at the group level in the present study did not translate to high test--retest reliability measures, which take into account both within-individual and between-individuals variability; while T50 was the most reliable post-cTBS time point (ICC = 0.53), T5 had very low reliability (ICC = 0.16). This pattern of results underlines the importance of calculating the ICCs of TMS measures rather than relying only on measures of inter-visit variability at the group level. Further, the low ICCs at T5 and T10 indicate that the time points expected to show maximal effects of cTBS ([@B117]) do not necessarily exhibit high test--retest reliability. This remained true for the cumulative measures of cTBS aftereffects over the first 20 min post-cTBS.

The very low test--retest reliability of ΔMEPs at T10 (ICC = 0.11) could be due to two factors: (1) The ΔMEPs at T10 in both visits could be the most influenced by *BDNF* polymorphism ([@B61]). Consistent facilitation of MEPs, at least numerically, in *BDNF* Met+ participants in both visits may have resulted in higher test--retest reliability of T10 ΔMEP in that subgroup ([Figure 5](#F5){ref-type="fig"}). (2) Despite the relatively long inter-visit interval in the present study, T10 seemed to exhibit a *metaplastic*-like effect similar to those reported with shorter intervals ([@B75]; [@B43]; [@B112]; [@B89]) in the overall results ([Figure 1](#F1){ref-type="fig"}), as well in the Younger group ([Figure 2A](#F2){ref-type="fig"}) and the *BDNF* Met-- subgroup ([Figure 4A](#F4){ref-type="fig"}). In all three cases, the direction of the neuromodulatory effect of cTBS at T10 was reversed, at least numerically, from inhibitory in visit-A to facilitatory in visit-B. Such reversals, when predominant at the individual level, would substantially reduce the test--retest reliability of cTBS aftereffects at T10. Although a previous iTBS study found only inter-visit intervals shorter than 7 days to be associated with metaplastic changes after iTBS in aging adults ([@B40]), the initial cTBS in the present study may have set into motion subtle changes that were still present when the second cTBS was applied. Further, it is possible that demographic, genetic, and state-dependent factors modulate the metaplastic(-like) effects of successive TBS sessions ([@B91]).

![Average ΔMEPs recorded from the right FDI muscle at 5 to 60 min following cTBS of the left primary motor cortex in two identical visits in the *BDNF* Met-- **(A)** and Met+ **(B)** groups. ^∗^The ΔMEPs in the *BDNF* Met-- group were significantly less than zero at T10 in visit-A (*P*~FDR~ = 0.042), but not at any other time point in either visit (*p*'s \> 0.14). The ΔMEPs in the *BDNF* Met+ group were not significantly different from zero at any time point in either visit (*P*~FDR~'s \> 0.05). Error bars represent standard error of the mean. *BDNF*, brain-derived neurotrophic factor; *BDNF* Met--, Val66Val; *BDNF* Met+, Val66Met; cTBS, continuous theta-burst stimulation; FDR, false discovery rate; ΔMEP, natural log-transformed, baseline-corrected; MEP amplitude; MEP, motor evoked potential; Met, metionine; Val, valine.](fnins-13-00447-g004){#F4}

The low test--retest reliability of several cTBS aftereffects resulted in adjustment of large- and medium effect sizes to medium and small effect sizes, respectively ([Table 3](#T3){ref-type="table"}). While calculating the cumulative cTBS measures improved the overall ICCs over T0--T30 and beyond ([Figure 3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}), the ICCs of the cumulative measures for the whole sample remained below 0.5. Attenuation of idealized effect sizes by this level of reproducibility indicates that detecting significant differences in cTBS responses between healthy and clinical populations may require sample sizes that are substantially larger than those used in most previous cTBS studies ([@B117]; [@B22]; [@B107]), unless steps can be implemented to improve the reliability of this technique.

![Test--retest reliability of baseline neurophysiological measures and post-cTBS ΔMEP measures separately in the *BDNF* Met--/Met+ and *APOE* ε4--/ε4+ groups. AUC of ΔMEPs were calculated as the summed products of the average ΔMEP across each two consecutive time-points and the time in minutes between them over T0--T10, T0--15, ..., T0--T60 intervals (marked by their end time point on the abscissa). The ICC values of RMT, AMT, and baseline MEP amplitude were not significantly different between the two *BDNF* groups (*p*'s \> 0.19) or the two *APOE* groups (*p*'s \> 0.16). Maximum suppression, maximum modulation, and the AUC of ΔMEPs over T0--T30 and beyond were significantly more reliable in the *BDNF* Met-- group than in the *BDNF* Met+ group (*P*~FDR~'s \< 0.032). The reliability of other cumulative ΔMEP measures was not significantly different between the two *BDNF* groups (*P*~FDR~ \> 0.208). All the AUC measures were significantly more reliable in the *APOE* ε4-- group than in the *APOE* ε4+ group (*P*~FDR~'s \< 0.021). The maximum suppression, maximum modulation were not significantly different between the two *APOE* groups (*P*~FDR~'s \> 0.27). AMT, active motor threshold; *APOE*, apolipoprotein E; *APOE* ε4+, ε2/ε4 or ε3/ε4 genotype; *APOE* ε4--, ε2/ε3 or ε3/ε3 genotype; AUC, area under-the-curve; *BDNF*, brain-derived neurotrophic factor; *BDNF* Met--, Val66Val; *BDNF* Met+, Val66Met; cTBS, continuous theta-burst stimulation; FDR, false discovery rate; ICC, intraclass correlation coefficient; ΔMEP, natural log-transformed, baseline-corrected MEP amplitude; MEP, motor evoked potential; Met, metionine; RMT, resting motor threshold; T0--T*n*, over the first *n* minutes following cTBS; Val, valine.](fnins-13-00447-g005){#F5}

The finding that within White, non-Hispanic, and right-handed males (*n* = 11), none of the ΔMEPs at any time point in either visit differed significantly from zero suggests that controlling for demographic factors such as gender, race/ethnicity, and handedness is not enough to overcome the large inter-individual variability in cTBS responses in either visit. We found, despite comparable reliability of baseline neurophysiological measures, T5 and T20--T50 ΔMEPs were substantially more reliable in this more-homogenous subgroup, suggesting that heterogeneity of these demographic factors influence the reliability of cTBS aftereffects in the whole sample. While the small sample precludes definitive conclusions about the effects of gender, handedness, and race/ethnicity, these results nonetheless appear to suggest that demographic variation plays a role in the test--retest reliability of cTBS responses.

Age and Reliability of cTBS Aftereffects
----------------------------------------

The significant *Age Group* × *Visit* interaction effect on T10 ΔMEP indicates that cTBS aftereffects at T10 in the Younger group, but not in the Older group, switched from inhibitory in visit-A to facilitatory in visit-B ([Figure 2](#F2){ref-type="fig"}). Such reversal could be due to metaplasticity or some other state-dependent factor. The distinct patterns of cTBS aftereffects at T10 among Younger and Older groups could be due to two factors: (i) Based on animal studies that have found an age-related reduction in the efficiency of gamma-aminobutyric acid- (GABA-) mediated inhibition ([@B80]; [@B9]; [@B79]), it is possible that older participants have less-efficient GABAergic synaptic transmission, which is presumed to be involved in cTBS-induced plasticity ([@B106]; [@B110]). The resulting reduced inhibitory effects of cTBS, potentially combined with cumulative facilitatory effects of successive single TMS pulses ([@B95]), could have resulted in facilitation of MEPs in the Older group, at least in visit-A. (ii) The finding that the Younger group, but not the Older group, showed metaplastic-like changes at T10 could be due to age-related differences in the priming effect of TBS ([@B91]), i.e., a stronger priming effect of cTBS in visit-A among younger participants.

Similarly, the finding that despite comparable ICCs of baseline neurophysiological measures in the two age groups, cTBS aftereffects were substantially less reliable in older participants ([Figure 3](#F3){ref-type="fig"}) could be due to the age-related decrease in the efficiency of GABAergic synaptic transmission reported in animal studies ([@B80]; [@B9]; [@B79]). These results indicate that in order to retain adequate power to detect differences in cTBS measures of plasticity in future studies, it may be necessary to adjust effect sizes separately for younger and older age groups.

*BDNF* and *APOE* Polymorphisms and Reliability of cTBS Aftereffects
--------------------------------------------------------------------

Despite comparable ICC values of RMT, AMT, and baseline MEP amplitude in *BDNF* Met-- and Met+ groups, cTBS aftereffects at several time points and most cumulative measures of cTBS aftereffects were substantially more reliable in *BDNF* Met-- participants than in Met+ participants ([Figure 5](#F5){ref-type="fig"}). This pattern of results could be due to the following: *BDNF* Met carrier status is known to be associated with impaired *N*-Methyl-[D]{.smallcaps}-aspartic acid- (NMDA-)dependent LTD ([@B118]), aberrant GABAergic synaptic transmission ([@B1]), reduced cTBS-induced inhibition of MEPs ([@B22]), and "paradoxical" cTBS-induced facilitation of MEPs in visit-A reported in our previous study ([@B61]) and a few other studies ([@B43]; [@B45]; [@B53]; [@B10]). The finding that *BDNF* Met+ participants showed MEP facilitation, at least numerically, at T10 in both visits ([Figure 4B](#F4){ref-type="fig"}) supports an association between *BDNF* Met+ status and facilitatory response to cTBS at T10 in the present sample. The noticeably lower test--retest reliability of cTBS aftereffects in *BDNF* Met+ participants ([Figure 5](#F5){ref-type="fig"}) could be due to the less-efficient cTBS-induced plasticity caused by aberrant GABAergic inhibition ([@B1]), assumed to be involved in the LTD-like effects of cTBS ([@B106]; [@B110]).

Despite comparable ICC values of RMT, AMT, and baseline MEP amplitude in *APOE* ε4-- and ε4+ participants, cTBS aftereffects at several time points and most cumulative measures of cTBS aftereffects were substantially more reliable in *APOE* ε4-- participants than in *APOE* ε4+ participants ([Figure 5](#F5){ref-type="fig"}). These results could be due to the influence of *APOE* ε4 on NMDA-mediated synaptic plasticity, which has been found to be involved in TBS aftereffects ([@B57]; [@B19]). These results are also consistent with the less-efficient rTMS-induced activation of brain networks in *APOE* ε4 carriers ([@B96]).

The small number of participants in the *BDNF* and *APOE* subgroups study limits the generalizability of the present findings on genetic influences on the test--retest reliability of cTBS measures. Assuming that the noticeable differences in reliability of cTBS aftereffects in *BDNF* and *APOE* subgroups observed here ([Figure 5](#F5){ref-type="fig"}) are confirmed in future studies, it would be advantageous to consider the expected proportions of *BDNF* and *APOE* subgroups and adjust effect sizes for each SNP subgroup accordingly. For example, the minor allele frequencies of rs6265 (*BDNF*), rs429358 (*APOE*), and rs7412 (*APOE*) SNPs in the admixed American population in the 1000 Genomes Project ([@B3]) are 0.1527, 0.1037, and 0.0476, respectively. As long as that the SNP frequencies among participants do not significantly deviate from Hardy--Weinberg equilibrium proportions ([@B47]; [@B116]), these frequencies provide good approximations to the frequencies of minor *BDNF* and *APOE* alleles in future cTBS studies.

In comparisons of test--retest reliability of cTBS measures between age or genetic subgroups, the finding that the subgroups in each case were comparable in gender, race/ethnicity, handedness, and the reliability of baseline neurophysiological measures indicates that differences in heterogeneity of demographic factors and baseline cortical excitability did not play a major role in the observed differences in test--retest reliability of cTBS aftereffects.

In addition to considering age, genetic polymorphisms, inter-visit interval ([@B40]), the time of day ([@B24]), and the use of neuronavigation ([@B62]), other factors that could improve the test--retest reliability of TMS measures include: ensuring comparable blood glucose levels and caffeine intake before and during each visit ([@B105]; [@B15]; [@B4]), comparable amount and quality of sleep the night before each visit ([@B23]; [@B68]), comparable intensity and duration of exercise before each visit ([@B100]; [@B70]), comparable phase of the menstrual cycle across visits ([@B104]; [@B51]), the use of robotic arms such as the TMS-Robot (Axilum Robotics, Schiltigheim, France), which can reduce trial-to-trial variability of MEP amplitude ([@B37]), comparable baseline MEP amplitude across plasticity visits ([@B40]), and implementing closed-loop systems that trigger TMS pulses timed to real-time, EEG-defined indices of brain states ([@B120], [@B121]).

Conclusion
==========

The present study assessed the test--retest reliability of cTBS aftereffects in healthy adults. cTBS aftereffects at most individual time points had low to moderate reliability. Cumulative cTBS measures over the first 30 min and beyond were relatively more reliable. Effect sizes adjusted for reliability of cTBS aftereffects are provided to help future studies retain adequate power for comparing M1 cTBS responses between healthy and clinical populations. Those calculations resulted in adjustment of several large and medium effect sizes to medium and small effect sizes, respectively, thereby substantially increasing the estimates of the required sample size to detect a significant difference in cTBS responses between healthy and clinical populations. Exploratory analyses found cTBS aftereffects were substantially more reliable in younger participants (age \< 35 years) and those with *BDNF* Met-- and *APOE* ε4-- genotypes.
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%Δ

:   percent change from the baseline

Δ~B-A~

:   visit-B *minus* visit-A

ΔMEP

:   natural log-transformed, baseline-corrected amplitude of motor evoked potentials

*APOE*

:   apolipoprotein E

AUC

:   area under-the-curve

*BDNF*

:   brain-derived neurotrophic factor

cTBS

:   continuous theta-burst stimulation

FDR

:   false discovery rate

GABA

:   gamma-aminobutyric acid

ICC

:   intraclass correlation coefficient

iTBS

:   intermittent theta-burst stimulation

LME

:   linear mixed-effects regression analysis

LTD

:   long-term depression

LTP

:   long-term potentiation

NMDA

:   *N*-Methyl-[D]{.smallcaps}-aspartic acid

PCR

:   polymerase chain reaction

Rm-ANOVA

:   repeated-measures analysis of variance

SNP

:   single-nucleotide polymorphism

T0--T*n*

:   over the first *n* minutes following cTBS

TMS

:   transcranial magnetic stimulation

T*n*

:   at *n* minutes post-cTBS
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